Clinical Trial Update: Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating pembrolizumab plus enfortumab vedotin for collecting duct carcinoma and renal medullary carcinoma, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Collecting Duct Carcinoma
• Renal Medullary Carcinoma

Drugs mentioned

• Enfortumab Vedotin (enfortumab vedotin)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Giuseppe Procopio | Conditions: Bellini Carcinoma, Collecting Duct Carcinoma | Phase 2 | Status: RECRUITING